Jasper Therapeutics, Inc. JSPR
are a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous
Urticaria ("CSU"), Chronic Inducible Urticaria ("CIndU") and asthma and we continue to consider additional indications
in mast cell driven diseases for potential future development. We have also historically explored development programs in diseases where
targeting diseased hemopoietic stem cells can provide benefits, such as stem cell transplant conditioning regimens, but those programs
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cost of revenue | $41.6M | $34.3M | — | — | — | — | — |
| R&D | $63.1M | $55.8M | $51.8M | $34.6M | $25.4M | $15.9M | — |
| SG&A | $20.8M | $20.4M | $17.1M | $16.6M | $11.4M | $4.8M | — |
| Total operating expenses | $83.9M | $76.2M | $68.9M | $51.2M | $36.8M | $20.7M | — |
| Operating income | -$83.9M | -$76.2M | -$68.9M | -$51.2M | $2.9M | -$20.7M | $2.9M |
| Interest expense | — | — | $246.0K | $115.0K | $80.0K | $111.0K | — |
| Pre-tax income | — | -$71.3M | -$64.5M | — | — | -$6.4M | — |
| Income tax | — | $2.0K | $2.0K | — | — | $38.5K | — |
| Net income | -$76 | -$71.3M | -$64.5M | -$37.7M | -$30.6M | -$31.7M | — |
| EPS, basic | -3.95 | -4.89 | -6.18 | -10.33 | -2.69 | — | — |
| EPS, diluted | -3.95 | -4.89 | -6.18 | -10.33 | -2.69 | -5.17 | — |
| Shares, diluted (wtd. avg.) | 19.2M | 14.6M | 10.4M | 3.6M | 11.4M | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | $28.7M | $71.6M | $87.3M | $38.7M | $85.0M | $20.2M | $27.2M |
| Total current assets | $34.6M | $75.8M | $88.9M | $41.7M | $87.8M | $20.7M | $1.5M |
| Property, plant and equipment | $102.0K | $1.9M | $2.7M | $3.6M | $3.7M | $693.0K | — |
| Total assets | $35.8M | $79.9M | $94.9M | $48.4M | $93.7M | $23.4M | $101.7M |
| Accounts payable | $6.2M | $4.0M | $4.1M | $1.8M | $3.9M | $1.4M | $95.1K |
| Total current liabilities | $13.2M | $15.2M | $12.4M | $7.1M | $8.0M | $4.0M | $111.4K |
| Total liabilities | $31.6M | $18.2M | $16.5M | $12.4M | $24.1M | $14.6M | $10.9M |
| Retained earnings | -$316.7M | -$240.9M | -$169.6M | -$105.1M | -$67.5M | -$36.8M | -$596.4K |
| Total equity | $4.2M | $61.7M | $78.4M | $36.0M | $69.5M | -$35.1M | -$4.7M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$77.2M | -$62.6M | -$52.1M | -$45.9M | -$33.7M | -$18.3M | — |
| Depreciation and amortisation | — | — | $1.1M | $975.0K | — | — | — |
| Stock-based compensation | $6.7M | $6.6M | $5.2M | $4.1M | $1.0M | $1.2M | — |
| Investing cash flow | $5.0K | -$532.0K | -$267.0K | -$576.0K | -$2.4M | $198.3K | — |
| Financing cash flow | $34.2M | $47.9M | $101.0M | $55.0K | $101.0M | $11.3M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001213900-26-068765.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — |
| Net income | — | -$31.7M | -$30.6M | -$37.7M | -$64.5M | -$71.3M | -$76 |
Recent filings and events
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Material agreement signed Item 1.01
- Acquisition or disposal completed A purchase or sale of a significant business or asset has closed. Item 2.01
- Unregistered share sale Shares issued outside a registered offering. Dilution, and for a small company often the way it is funded. Item 3.02
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Charter or fiscal year changed A change to the company's governing documents, or to when its year ends. Item 5.03
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Regulation FD disclosure Item 7.01
- Delisting notice The exchange has told the company it no longer meets the rules for staying listed - usually price, market cap, or filings that are late. Item 3.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2836
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AMGN | AMGEN INC | $237.48B | 30.9x | 10.0% |
| GILD | GILEAD SCIENCES, INC. | $193.48B | 23.0x | 2.4% |
| MRNA | Moderna, Inc. | $79.89B | — | -39.9% |
| RVMD | Revolution Medicines, Inc. | $40.08B | — | — |
| BIIB | BIOGEN INC. | $37.01B | 28.5x | 2.2% |
| EXEL | EXELIXIS, INC. | $15.99B | 23.2x | 7.0% |
| NBIX | NEUROCRINE BIOSCIENCES INC | $14.51B | 30.6x | 21.4% |
| HALO | HALOZYME THERAPEUTICS, INC. | $14.26B | 49.1x | 37.6% |